Publications

Publications 2011

A RANDOMIZED PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY WITH IRINOTECAN, LEUCOVORIN AND FLUOROURACIL VERSUS LEUCOVORIN AND FLUOROURACIL FOR STAGE II AND III COLON CANCER: A HELLENIC COOPERATIVE ONCOLOGY GROUP STUDY

C.A. Papadimitriou, P. Papakostas, M. Karina, L. Malettou, M.A. Dimopoulos, G. Pentheroudakis, E. Samantas, A. Bamias, D. Miliaras, G. Basdanis, N. Xiros, G. Klouvas, D. Bafaloukos, G. Kafiri, I. Papaspirou, D. Pectasides, C. Karanikiotis, T. Economopoulos, I. Efstratiou, I. Korantzis, N. Pisanidis, T. Makatsoris, F. Matsiakou, G. Aravantinos, H. P. Kalofonos, G. Fountzilas

BMC Med 2011 Jan 31;9:10


 

ALL ABOUT KRAS FOR CLINICAL ONCOLOGY PRACTICE: GENE PROFILE, CLINICAL IMPLICATIONS AND LABORATORY RECOMMENDATIONS FOR SOMATIC MUTATIONAL TESTING IN COLORECTAL CANCER

H. Linardou, E. Briasoulis, I.J. Dahabreh, G. Mountzios, C. Papadimitriou, S. Papadopoulos, D. Bafaloukos, P. Kosmidis, S. MurrayCancer

Cancer Treat Rev 2011 May;37(3):221-33 [Epub 2010 Sep 29]


 

STAT RELATED PROFILES ARE ASSOCIATED WITH PATIENT RESPONSE TO TARGETED TREATMENTS IN LOCALLY ADVANCED SCCHN

V. Kotoula, S. Lambaki, D. Televantou, A. Kalogera-Fountzila, A. Nikolaou, K. Markou, D. Misailidou, K.N. Syrigos, G. Fountzilas

Transl Oncol 2011 Feb 1;4(1):47-58

 


 

 

COMPARATIVE PROGNOSTIC VALUE OF EPIDERMAL GROWTH FACTOR QUANTITATIVE PROTEIN EXPRESSION COMPARED WITH FISH FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA

E. Pectasides, T. Rampias, P. Kountourakis, C. Sasaki, D. Kowalski, G. Fountzilas, T. Zaramboukas, D. Rimm, B. Burtness, A. Psyrri

Clin Cancer Res 2011 May 1;17(9):2947-54 [Epub 2011 Feb 25]

 


 

 

PACLITAXEL AND GEMCITABINE VERSUS PACLITAXEL AND VINORELBINE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER. A PHASE III STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG)

P.A. Kosmidis, G. Fountzilas, A.G. Eleftheraki, H.P. Kalofonos, G. Pentheroudakis, D. Skarlos, M.A. Dimopoulos, D. Bafaloukos, D. Pectasides, E. Samantas, I. Boukovinas, S. Lambaki, N. Katirtzoglou, C. Bakogiannis & K.N. Syrigos

Annals of Oncology 2011 Apr;22(4):827-34 [Epub 2010 Sep 29]

 


 

EGFR GENE COPY NUMBER AS A PREDICTIVE BIOMARKER FOR PATIENTS RECEIVING TYROSINE KINASE INHIBITOR TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS IN NON-SMALL CELL LUNG CANCER

I.J. Dahabreh, H. Linardou, P. Kosmidis, D. Bafaloukos, S. Murray

Annals of Oncology 2011 Mar;22(3):545-52. [Epub 2010 Sep 8]


 

MECHANISMS OF RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: CLINICAL AND MOLECULAR CONSIDERATIONS

A. Pallis, E. Briasoulis, H. Linardou, C. Papadimitriou, D. Bafaloukos, P. Kosmidis, S. Murray

Current Medicinal Chemistry 2011;18(11):1613-28

 


 

 

PROGNOSTIC UTILITY OF Β-TUBULIN ISOTYPE III AND CORRELATIONS WITH OTHER MOLECULAR AND CLINICOPATHOLOGICAL VARIABLES IN PATIENTS WITH EARLY BREAST CANCER: A TRANSLATIONAL HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

G. Pentheroudakis, A. Batistatou, K.T. Kalogeras, R. Kronenwett, R.M. Wirtz, E. Bournakis, A.G. Eleftheraki, D. Pectasides, M. Bobos, D. Miliaras, I. Papaspirou, S. Kamina, H. Gogas, A.K. Koutras, N. Pavlidis, G. Fountzilas

Breast Cancer Research and Treatment 2011 May;127(1):179-93. [Epub 2011 Mar 9]

 


 

 

REPORT OF THE LONG-TERM EFFICACY OF TWO CYCLES OF ADJUVANT BLEOMYCIN/ETOPOSIDE/CISPLATIN IN PATIENTS WITH STAGE I TESTICULAR NONSEMINOMATOUS GERM-CELL TUMORS (NSGCT): A RISK ADAPTED PROTOCOL OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP

A. Bamias, G. Aravantinos, I. Kastriotis, G. Alivizatos, I. Anastasiou, C. Christodoulou, R. Gyftaki, H.P Kalofonos, M.A Dimopoulos

Urologic Oncology 2011 Mar-Apr;29(2):189-93. [Epub 2009 Apr 11]

 


 

PACLITAXEL AND BEVACIZUMAB, AS FIRST LINE COMBINED TREATMENT, IN PATIENTS WITH METASTATIC BREAST CANCER.THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOLOGICAL MARKER EVALUATION

G. Fountzilas, H.P. Kourea, M. Bobos, D. Televantou, V. Kotoula, C. Papadimitriou, K.T. Papazisis, E. Timotheadou, I. Efstratiou, A. Koutras, G. Pentheroudakis, C. Christodoulou, G. Aravantinos, D. Miliaras, K. Petraki, C.N. Papandreou, P. Papakostas, D. Bafaloukos, D. Repana, E. Razis, D. Pectasides, A.M. Dimopoulos

Anticancer Research 2011 Sep;31(9):3007-18


 

RELEVANCE OF HER2 AND TOP2A PARAMETERS AS PROGNOSTIC FACTORS IN HIGH-RISK EARLY BREAST CANCER PATIENTS TREATED WITH ADJUVANT EPIRUBICIN-BASED DOSE-DENSE SEQUENTIAL TREATMENT IN THE CONTEXT OF HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMIZED TRIAL

G. Fountzilas, Ch. Valavanis, V. Kotoula, A.G. Eleftheraki, K.T. Kalogeras, O. Tzaida, A. Batistatou, R. Kronenwett, R.M. Wirtz, M. Bobos, E.Timotheadou, N. Soupos, G. Pentheroudakis, H. Gogas, D. Vlachodimitropoulos, G. Polychronidou, G. Aravantinos, A. Koutras, Ch. Christodoulou, D. Pectasides, and P. Arapantoni

Journal of Translational Medicine, On line

 


 

VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS AND CLINICAL OUTCOME IN COLORECTAL CANCER PATIENTS TREATED WITH IRINOTECAN-BASED CHEMOTHERAPY AND BEVACIZUMAB IN THE FIRST-LINE SETTING

A.K. Koutras, A. Antonacopoulou, A.G. Eleftheraki, A. Koumarianou, I. Varthalitis, F. Fostira, I. Sgouros, E. Briasoulis, E. Bournakis, D. Bafaloukos, I. Bombolaki, E. Galani, D. Pectasides, G. Foutzilas, H.P. Kalofonos

Pharmacogenomics J. 2011 Aug 16. doi: 10.1038/tpj.2011.37. [Epub ahead of print]

 


 

 

INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY AND WEEKLY CISPLATIN VERSUS THE SAME CONCOMITANT CHEMORADIOTHERAPY IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA: A RANDOMIZED PHASE II STUDY CONDUCTED BY THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) WITH BIOMARKER EVALUATION

G. Fountzilas, E. Ciuleanu, M. Bobos, A. Kalogera-Fountzila, A.G Eleftheraki, G. Karayannopoulou, T. Zaramboukas, A. Nikolaou, K. Markou, L. Resiga, D. Dionysopoulos, E. Samantas, H. Athanassiou, D. Misailidou, D. Skarlos, T. Ciuleanu

Annals of Oncology, 2012 Feb;23(2):427-35. [Epub 2011 Apr 27]

 


 

 

EVALUATION OF THE ASSOCIATION OF PIK3CA MUTATIONS AND PTEN LOSS WITH EFFICACY OF TRASTUZUMAB THERAPY IN METASTATIC BREAST CANCER

E.Razis, M. Bobos, V. Kotoula, A.G. Eleftheraki, H.P. Kalofonos, K. Pavlakis, P. Papakostas, G. Aravantinos, G. Rigakos, I. Efstratiou, K. Petraki, D. Bafaloukos, I. Kostopoulos, D. Pectasides, K.T. Kalogeras, D. Skarlos, G. Fountzilas

Breast Cancer Research and Treatment 2011 Jul;128(2):447-56. [Epub 2011 May 19]

 


 

 

COMMON BREAST CANCER SUSCEPTIBILITY LOCI ARE ASSOCIATED WITH TRIPLE NEGATIVE BREAST CANCER

K.N Stevens, C.M Vachon, A.M Lee, S. Slager, T. Lesnick, C. Olswold, P.A Fasching, P. Miron, D. Eccles, J.E Carpenter, A.K Godwin, C. Ambrosone, R. Winqvist, H. Brauch H; GENICA consortium, M.K Schmidt, A. Cox, S.S Cross, E. Sawyer, A. Hartmann, M.W Beckmann, R. Schulz-Wendtland, A.B Ekici, W.J Tapper, S.M Gerty, L. Durcan, N. Graham, R. Hein, S. Nickels, D. Flesch-Janys, J. Heinz, H.P Sinn, I. Konstantopoulou, F. Fostira, D. Pectasides, A.M Dimopoulos, G. Fountzilas, C.L Clarke, R. Balleine, J.E Olson, Z. Fredericksen, R.B Diasio, H. Pathak, E. Ross, J. Weaver, T. Rüdiger, A. Försti, T. Dünnebier, F. Ademuyiwa, S. Kulkarni, K. Pylkäs, A. Jukkola-Vuorinen,Y.D Ko, E. Van Limbergen, H. Janssen, J. Peto, O. Fletcher, G.G Giles, L. Baglietto, S. Verhoef, I. Tomlinson, V.M Kosma, J. Beesley, D. Greco, C. Blomqvist, A. Irwanto, J. Liu, F.M Blows, S.J Dawson, S. Margolin, A. Mannermaa, N.G Martin, G.W Montgomery, D. Lambrechts, I. dos Santos Silva, G. Severi, U. Hamann, P. Pharoah, D.F Easton, J. Chang-Claude, D. Yannoukakos, H. Nevanlinna, X. Wang, F.J Couch

Cancer Research, 2011 Oct 1;71(19):6240-9. [Epub 2011 Aug 15]

 


 

 

A COMMON VARIANT AT THE TERT/CLPTM1L LOCUS IS ASSOCIATED WITH ESTROGEN RECEPTOR-NEGATIVE BREAST CANCER

C.A Haiman, G.K Chen, C.M Vachon, F. Canzian, A. Dunning, R.C Millikan, X. Wang, F. Ademuyiwa, S. Ahmed, C.B Ambrosone, L. Baglietto, R. Balleine, E.V Bandera, M.W Beckmann, C.D Berg, L. Bernstein, C. Blomqvist, W.J Blot, H. Brauch, J.E Buring, L.A Carey, J.E Carpenter, J. Chang-Claude, S.J Chanock, D.I Chasman, C.L Clarke, A. Cox, S.S Cross, S.L Deming, R.B Diasio, A.M Dimopoulos, W.R Driver, T. Dünnebier, L. Durcan, D. Eccles, C.K Edlund, A.B Ekici, P.A Fasching, H.S Feigelson, D. Flesch-Janys, F. Fostira, A. Försti, G. Fountzilas, S.M Gerty; Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium, G.G Giles, A.K Godwin, P. Goodfellow, N. Graham, D. Greco, U. Hamann, S.E Hankinson, A. Hartmann, R. Hein, J. Heinz, A. Holbrook, R.N Hoover, J.J Hu, D.J Hunter, S.A Ingles, A. Irwanto, J. Ivanovich, E.M John, N. Johnson, A. Jukkola-Vuorinen, R. Kaaks, Y.D Ko, L.N Kolonel, I. Konstantopoulou, V.M Kosma, S. Kulkarni, D. Lambrechts, A.M Lee, L.L Marchand, T. Lesnick, J. Liu, S. Lindstrom, A. Mannermaa, S. Margolin, N.G Martin, P. Miron, G.W Montgomery, H. Nevanlinna, S. Nickels, S. Nyante, C. Olswold, J. Palmer, H. Pathak, D. Pectasides, C.M Perou, J. Peto, P.D Pharoah, L.C Pooler, M.F Press, K. Pylkäs, T.R Rebbeck, J.L Rodriguez-Gil, L. Rosenberg, E. Ross, T. Rüdiger, S. Silva Idos, E. Sawyer, M.K Schmidt, R. Schulz-Wendtland, F. Schumacher, G. Severi, X. Sheng, L.B Signorello, H.P Sinn, K.N Stevens, M.C Southey, W.J Tapper, I. Tomlinson, F.B Hogervorst, E. Wauters, J. Weaver, H. Wildiers, R. Winqvist, D. Van Den Berg, P. Wan, L.Y Xia , D. Yannoukakos, W. Zheng, R.G Ziegler, A. Siddiq, S.L Slager, D.O Stram, D. Easton, P. Kraft, B.E Henderson, F.J Couch

Nature Genetics, 2011 Oct 30;43(12):1210-4. doi: 10.1038/ng.985

 


 

 

TRIPLE-NEGATIVE PHENOTYPE IS OF ADVERSE PROGNOSTIC VALUE IN PATIENTS TREATED WITH DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY: A TRANSLATIONAL RESEARCH ANALYSIS IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG) RANDOMIZED PHASE III TRIAL

P. Skarlos, C. Christodoulou, K.T Kalogeras, A.G Eleftheraki, M. Bobos, A. Batistatou, C. Valavanis, O. Tzaida, E. Timotheadou, R. Kronenwett, R.M Wirtz, I. Kostopoulos, D. Televantou, E. Koutselini, I. Papaspirou, C.A Papadimitriou, D. Pectasides, H. Gogas, G. Aravantinos, N. Pavlidis, P. Arapantoni, D.V Skarlos, G. Fountzilas

Cancer Chemotherapy Pharmacology [Epub 2011 Sep 8]

 


 

 

POSTOPERATIVE DOSE-DENSE SEQUENTIAL VERSUS CONCOMITANT ADMINISTRATION OF EPIRUBICIN AND PACLITAXEL IN PATIENTS WITH NODE-POSITIVE BREAST CANCER: 5-YEAR RESULTS OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP. HE 10/00 PHASE III TRIAL

H. Gogas, U. Dafni, M. Karina, C. Papadimitriou, A. Batistatou, M. Bobos, H.P Kalofonos, A.G Eleftheraki, E. Timotheadou, D. Bafaloukos, C. Christodoulou, C. Markopoulos, E. Briasoulis, P. Papakostas, E. Samantas, P. Kosmidis, G.P Stathopoulos, C. Karanikiotis, D. Pectasides, M.A Dimopoulos, G. Fountzilas

Breast Cancer Research and Treatment [Epub 2011 Dec 21]

 


 

EXPRESSION OF ANGIOGENIC MARKERS IN THE PERIPHERAL BLOOD OF DOCETAXEL-TREATED ADVANCED BREAST CANCER PATIENTS. A HELLENIC ONCOLOGY GROUP (HECOG) STUDY

D. Pectasides, G. Papaxoinis, V. Kotoula, H. Fountzilas, I. Korantzis, A. Koutras, A.M. Dimopoulos, P. Papakostas, G. Aravantinos, I. Varthalitis, P. Kosmidis, D. Skarlos, E. Bournakis, D. Bafaloukos, H.P. Kalofonos, K.T. Kalogeras, G.Fountzilas

Oncology Reports, doi: 10.3892/or.2011.1504. [Epub 2011 Oct 13]